Goldman Sachs already appears to be having second thoughts on its tepid forecast for 2015.
Blackstone Group economic prognosticator Byron Wien thinks there's plenty of reason for optimism in 2015.
U.S. crude oil fell to a fresh five-year low on Monday, starting December on a downbeat, and charts suggest further downside ahead.
A small group of elite investors are behind Uber's latest fundraising effort and believe the company is set for a massive IPO.
Friday's turbocharged jobs headline came thanks to seasonal adjustments and other wizardry at the Bureau of Labor Statistics.
Buffett's contribution to a presumed Clinton presidential run is not as big a departure from his anti-PAC principles as it appears.
The best performing sector on days when the jobs report beat estimates by more than 80,000 jobs was financials.
The best and worst performing stocks when jobs data surprises
Central banks are creating a "point of low return" for investors, Gross told clients.
European stocks weakened and the euro shot higher as the ECB chief implied any initiative to purchase sovereign debt isn't imminent.
No one can be sure how far oil will fall, but investors soon are likely to begin picking their spots and buying up beaten-down energy stocks.
A strange series of very heavy trading has Wall Street traders scratching their heads.
Activist investor Trian Fund Management secured another partial victory on Tuesday by landing a seat on the board of BNY Mellon.
Brown-Forman's soft earnings were about forex headwinds, not flagging demand. The same can't be said for Abercrombie & Fitch.
Wall Street's biggest fight of the year focused on high-frequency trading, so it's probably fitting that 2014 ends with another round.
The pace of hedge fund failures is picking up after another year of relatively weak returns.
The Chinese market is looking attractive, but investors must learn the difference between shares traded inside and outside the mainland.
Apple dropped five percent around 9:50 a.m. ET from $117 to $111. Plausible reasons: Fat-finer trade and/or a very large seller.
Fresh of a big win from investing in human drugs, Bill Ackman is now focused on pharmaceuticals for animals.
One pro says the hedge fund industry has put in safeguards to make sure the next crisis is nowhere near as bad as the last.
Get the best of CNBC in your inbox